OsimertinibDrug resistance secondary to C797S mutation and pneumonitis : 2 case reports

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1740卷 / 1期
关键词：
D O I：
10.1007/s40278-019-58148-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：255 / 255
相关论文
共 50 条
  • [41] Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy
    Xu, Li
    Xu, Bing
    Wang, Jianshe
    Gao, Yuan
    He, Xingrui
    Xie, Tian
    Ye, Xiang-Yang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 245
  • [42] Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).
    Janne, Pasi A.
    Lee, Jessica Kim
    Madison, Russell
    Venstrom, Jeffrey Michael
    Schrock, Alexa Betzig
    Oxnard, Geoffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] H002: A wide spectrum, highly selective fourth-generation EGFR inhibitor overcoming resistance harboring C797S mutation in NSCLC
    Huang, Wei
    Zhu, Lin
    Yan, Xiaoe
    Huang, Xin
    Hao, Jia
    Li, Shan
    Li, Xiangyu
    Chen, Zhiming
    Jia, Yunchuan
    Li, Haibo
    Zhang, Jianming
    Deng, Xianming
    Yun, Caihong
    CANCER RESEARCH, 2022, 82 (12)
  • [44] Therapeutic or Prophylactic Targeting C797S in EGFR Mutant Lung Adenocarcinoma
    Guan, X. -H.
    Weng, C. -D.
    Chen, H. -J.
    Zhou, Q.
    Zhang, X. -C.
    Wu, Y. -L.
    Yang, J. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S656 - S656
  • [45] Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review
    Mansour, Mostafa A.
    AboulMagd, Asmaa M.
    Abbas, Samar H.
    Abdel-Rahman, Hamdy M.
    Abdel-Aziz, Mohamed
    RSC ADVANCES, 2023, 13 (27) : 18825 - 18853
  • [46] Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib
    Wang, Zhen
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : E81 - E82
  • [47] TRX-221, a novel 4th-generation EGFR inhibitor for overcoming C797S mutation-mediated acquired resistance in NSCLC
    Lim, Sumin
    Choi, Seulgi
    Lee, Ju-Kyung
    Choi, Eunhyun
    Lee, Sungwon
    Chun, Kwangwoo
    Baek, Myoungki
    Park, Jiyeon
    Kim, Jihyun
    Kang, Areum
    Kim, Younghoon
    Kim, Namkyoung
    Cho, Byoungchul
    Sim, Taebo
    Lee, Koo
    CANCER RESEARCH, 2023, 83 (07)
  • [48] OsimertinibDrug-induced liver injury : 2 case reports
    Reactions Weekly, 2024, 2017 (1) : 402 - 402
  • [49] High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
    Osoegawa, Atsushi
    Yamaguchi, Masafumi
    Nakamura, Tomomi
    Morinaga, Ryotaro
    Tanaka, Kentaro
    Kashiwabara, Kosuke
    Miura, Takashi
    Suetsugu, Takayuki
    Harada, Taishi
    Asoh, Tatsuma
    Taguchi, Kenichi
    Nabeshima, Kazuki
    Kishimoto, Junji
    Sakai, Kazuko
    Nishio, Kazuto
    Sugio, Kenji
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (07):
  • [50] VismodegibDevelopment of secondary resistance: 2 case reports
    Reactions Weekly, 2019, 1784 (1) : 260 - 260
12345